Patients who traveled to high-volume centers for esophagectomy experienced better outcomes than those who sought treatment ...

Bart Frazzitta was told he had a 5% chance of surviving esophageal cancer. Twenty-five years later, he's still here and ...

Bart Frazzitta was told he had a 5% chance of surviving esophageal cancer. Twenty-five years later, he's still here and helping others.

David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, ...

In a remarkable medical achievement, an 86-year-old man presented to Manipal Hospital Vijayawada with a long-standing history ...

Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding ...

Leap Therapeutics (LPTX) announced positive initial data from Part B of the DeFianCe study evaluating sirexatamab in combination with ...

Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric ...

US clinical-stage immuno-oncology biotech ALX Oncology Holdings released positive updated data from the ASPEN-06 Phase II ...

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...

Conversion therapy has become a hot topic among specialists in gastrointestinal cancers, said Pamela Kunz, MD, of the Yale ...

Researchers compare nivolumab as monotherapy or in combination with chemotherapy vs conventional treatment on overall survival and progression-free survival in patients with advanced unresectable ...